Compare Inovio Pharmaceuticals Inc (INO) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while SYSCO Corporation trades at $81.4 (market cap $38.63B). The key difference: SYSCO Corporation is far larger — about 432.7× Inovio Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.72% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SYY | |
|---|---|---|
Market Cap | $89.27M | $38.63B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $91.16 |
52-Week Low | $1.05 | $69.30 |
Enterprise Value | $60.28M | $52.11B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SYY trades at $81.02, down 0.82% on the day, with a neutral technical signal and support at $81. The company reported $81.37B in revenue for 2025 with a net margin of 2.08%, and upcoming Q4 2026 earnings on August 4 are expected at $1.51 EPS. Positive cash flow trends and a dividend of $0.55 payable July 24 provide stability, while analyst consensus is bullish with a $84.75 price target.
Outlook is cautiously optimistic given analyst buy ratings (60%) and steady revenue growth, but risks include thin profit margins and high debt levels. The stock offers value with a P/S of 0.47, though near-term performance hinges on earnings results and macroeconomic conditions affecting the food distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
